Ondine Biomedical Inc. Result of AGM and Voting Results

RNS Number : 4565U

Ondine Biomedical Inc.

28 June 2024

 

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Result of AGM and voting results

Ondine Biomedical (AIM: OBI) announces that at its Annual General Meeting held on 28 June 2024 all resolutions were duly passed.

The voting results of the AGM were as follows:

	In Favor		Against		Withheld
Resolution	Votes	%	Votes	%	Votes
1. Election of Directors
Carolyn Cross	191,380,245	100.00	0	0.00	0
Nicolas G. Loebel	191,380,245	100.00	0	0.00	0
Jean Charest	190,741,872	99.67	0	0.00	638,373
Jean Duvall	190,741,872	99.67	0	0.00	638,373
Junaid Bajwa	190,741,872	99.67	0	0.00	638,373
Michael Farrar	190,741,872	99.67	0	0.00	638,373
Craig Tooman	190,741,872	99.67	0	0.00	638,373
2. Appointment of Auditors	191,380,245	100.00	0	0.00	0

 

Enquiries:

​

Ondine Biomedical Inc.
Carolyn Cross, CEO	+001 [phone]
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Sam Butcher, Jalini Kalaravy	[phone]
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe, the UK-CA mark, and is approved in Canada and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGEAKKPADNLEFA